Skipar K, Hompland T, Lund KV, Fjeldbo CS, Lindemann K, Hellebust TP, Lyng H, Bruheim K(2025) Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: A phase II, randomized study Acta Oncol, 64, 439-447 DOI 10.2340/1651-226X.2025.43045, PubMed 40105683
Wang R, Gunesli GN, Skingen VE, Valen KF, Lyng H, Young LS, Rajpoot N(2025) Deep learning for predicting prognostic consensus molecular subtypes in cervical cancer from histology images NPJ Precis Oncol, 9(1), 11 DOI 10.1038/s41698-024-00778-5, PubMed 39799271
Skingen VE, Salberg UB, Hompland T, Fjeldbo CS, Helgeland H, Frikstad KM, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H(2024) Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer J Pathol, 264(3), 270-283 DOI 10.1002/path.6344, PubMed 39329425
Heidi Lyng, Department of Radiation Biology, Institute for Cancer Research Norwegian Radium Hospital, Oslo University Hospital Phone +47 22 78 1478, e-mail: heidi.lyng@ous-hf.no
